TABLE 1

Baseline demography

rs1225372rs7903146
AllGGGTTTANOVACCCTTTANOVA
Patients started on sulfonylureas
    n901382415104380409112
    Age at Rx (years)63.8 ± 9.663.8 ± 9.663.9 ± 9.863.7 ± 8.90.9963.8 ± 9.864.1 ± 9.662.9 ± 8.70.53
    Age at diagnosis (years)61.3 ± 9.661.5 ± 9.461.3 ± 9.860.9 ± 9.70.8461.6 ± 9.661.3 ± 9.760.2 ± 9.30.40
    BMI average (kg/m2)28.3 ± 4.628.3 ± 4.528.4 ± 4.527.6 ± 4.70.2628.4 ± 4.628.3 ± 4.627.7 ± 4.40.37
    BMI at diagnosis (kg/m2)*28.1 ± 4.627.9 ± 4.628.5 ± 4.826.8 ± 3.50.02028.1 ± 4.728.4 ± 4.727.0 ± 3.50.049
    BMI at start of treatment28.0 ± 4.528.0 ± 4.628.2 ± 4.627.0 ± 3.30.0928.2 ± 4.828.1 ± 4.627.1 ± 3.30.13
    Sex (% male)585759630.555857630.63
    Dose (% maximum)28 ± 1528 ± 1429 ± 1629 ± 150.7528 ± 1529 ± 1528 ± 140.84
    Adherence (%)80 ± 1880 ± 1879 ± 1883 ± 150.09279 ± 1880 ± 1782 ± 150.31
Metformin
    n9454344209142242499
    Age at Rx (years)60.0 ± 9.560.4 ± 9.759.5 ± 9.061.2 ± 10.50.1760.5 ± 9.659.5 ± 9.260.6 ± 9.90.24
    Age at diagnosis (years)57.7 ± 9.458.2 ± 9.556.9 ± 8.959.2 ± 10.40.04158.3 ± 9.457.0 ± 9.158.4 ± 9.90.11
    BMI average (kg/m2)32.8 ± 5.633.4 ± 5.732.4 ± 5.431.4 ± 5.50.00233.3 ± 5.732.6 ± 5.431.2 ± 5.50.003
    BMI at diagnosis (kg/m2)33.1 ± 6.034.0 ± 6.332.4 ± 5.631.8 ± 5.6<0.00134.0 ± 6.332.6 ± 5.631.5 ± 5.50.001
    BMI at start of treatment§32.9 ± 5.833.6 ± 5.932.5 ± 5.631.3 ± 5.70.00133.5 ± 6.032.6 ± 5.531.2 ± 5.60.001
    Sex (% male)524756480.0264954530.28
    Dose (% maximum)19 ± 719 ± 719 ± 619 ± 50.3819 ± 719 ± 719 ± 70.50
    Adherence (%)92 ± 1291 ± 1392 ± 1192 ± 110.2691 ± 1492 ± 1193 ± 110.16
  • Data are means ± SD unless otherwise indicated. P < 0.05 are bold.

  • * n = 643;

  • n = 800;

  • n = 761;

  • § n = 893. Rx, treatment.